Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yong Wu has a total of 75 co-authors. Here are the top co-authors by number of shared publications:

  • Pengfei She

    Department of Laboratory Medicine, The Third Xiangya Hosipital of Central South University, Changsha, China

    35 shared publications
  • Linying Zhou

    Department of Laboratory Medicine, The First Hospital of Changsha (Affiliated Changsha Hospital of Xiangya, School of Medicine Central South University), Changsha, China

    22 shared publications
  • Yimin Li

    The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, China

    21 shared publications
  • Shasha Liu

    Department of Laboratory Medicine, the third Xiangya Hospital of Central South University, Changsha, China

    14 shared publications
  • Zehao Li

    Department of Laboratory Medicine, the third Xiangya Hospital of Central South University, Changsha, China

    14 shared publications
  • Lanlan Xu

    Department of Laboratory Medicine, Third Xiangya Hospital of Central South University , Changsha 410005 , China

    13 shared publications

Latest Publications

  • INE963: A repurposed antiparasitic combating methicillin-resistant Staphylococcus aureus and colistin-resistant Acinetobacter baumannii

    by Pengfei She, Yiqing Liu, Mengna Li, Lihua Lu, Yelan Hong, Muqi Liu, Yanping Sun, Yimin Li, Linying Zhou, Yong Wu

  • Open Access

    INE963: a repurposed antiparasitic combating methicillin-resistant Staphylococcus aureus and colistin-resistant Acinetobacter baumannii

    by Pengfei She, Yiqing Liu, Mengna Li, Lihua Lu, Yelan Hong, Muqi Liu, Yanping Sun, Yimin Li, Linyin Zhou, Yong Wu

    The emergence of multidrug-resistant bacteria, particularly methicillin-resistant Staphylococcus aureus (MRSA) and colistin-resistant Acinetobacter baumannii, necessitates novel antibacterial strategies. Via high-throughput screening of an FDA-approved drug library, we identified the antiparasitic small molecule INE963 as a multi-function antibacterial candidate. Against MRSA, INE963 exerted potent bactericidal activity with low resistance propensity. Mechanistically, it targeted phosphatidylglycerol in the bacterial membrane, disrupted the proton motive force and thereby induced energy metabolism disorder and a lethal burst of reactive oxygen species. INE963 also downregulated the Agr quorum sensing system, suppressed biofilm formation and eradicated preformed biofilms. In terms of colistin-resistant A. baumannii, INE963 directly bound to lipopolysaccharide and synergized with colistin to restore bacterial susceptibility, which compromised membrane integrity, depolarized membrane potential, disrupted proton motive force and caused ATP depletion and oxidative stress. In vivo, INE963 monotherapy exhibited robust efficacy in murine models of MRSA-related wound infection, peritonitis and implant-associated osteoarthritis, reducing bacterial loads, accelerating wound healing and preventing bone destruction. The combination of INE963 and colistin was effective in colistin-resistant A. baumannii peritonitis, attenuating systemic bacterial dissemination and tissue pathology. Comprehensive safety assessments confirmed low cytotoxicity and no overt organ toxicity at therapeutic doses. In all, INE963 is a promising multi-function antibacterial agent integrating direct membrane targeting, virulence neutralization and colistin sensitization, providing a novel strategy to combat MRSA and colistin-resistant A. baumannii infections.

  • Open Access

    Resorantel: a dual-targeting therapeutic with potent efficacy against Staphylococcus aureus with low potential for drug resistance

    by Pengfei She, Shaowei Guo, Dan Xiao, Guanqing Huang, Yiqing Liu, Mengna Li, Lihua Lu, Yelan Hong, Yong Wu

    Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a significant public health concern. The biofilm formation capability of MRSA is often associated with high levels of antimicrobial resistance. Therefore, the development of novel therapeutic strategies to combat MRSA is urgently warranted. By drug repurposing, resorantel, originally developed as an antiparasitic agent, has demonstrated significantly bactericidal activity against MRSA and its biofilms with effectively inhibitory activity against the emergence of drug resistance. Furthermore, resorantel displayed significant in vivo antibacterial efficacy in both topic and systemic infection models. Mechanistic investigations employing transcriptomics, fluorescent probes, molecular dynamics simulations, and surface plasmon resonance analysis revealed that proton motive force and MurB are likely the potential targets of resorantel. Collectively, this study identifies resorantel as a promising novel antimicrobial agent with potential for use in the treatment of MRSA and its biofilm-related infections.

  • Open Access

    Drug repurposing: a dual-mechanism antibiotic combats MRSA and its high resistant phenotypes

    by Pengfei She, Dan Xiao, Guanqing Huang, Shaowei Guo, Yiqing Liu, Mengna Li, Lihua Lu, Yelan Hong, Yong Wu

    Purpose: Methicillin-resistant Staphylococcus aureus (MRSA) is frequently observed in biofilm form, exhibiting significant tolerance, particularly in the context of deep tissue infections such as osteomyelitis. This characteristic renders clinical treatment extremely challenging. Therefore, the development of novel antibacterial agents against MRSA and its biofilms is identified as an urgent priority. Methods: By drug repurposing, this study determines the antibacterial activity of the anti-amoebic small molecule tiliquinol against MRSA and its highly drug-resistant biofilms and evaluates its potential to induce MRSA resistance. The antibacterial mechanism of tiliquinol is examined utilizing transcriptomics, fluorescent probes, and quantitative reverse-transcription polymerase chain reaction. In addition, we evaluate in vivo antibacterial efficacy and safety profiles by established multiple murine infection models, including skin and soft tissue infection, sepsis, as well as the periprosthetic joint infection. Results: The research find that tiliquinol exhibits notable antibacterial activity against MRSA and its highly resistant biofilms avoiding resistance occurrence. Mechanism study reveals that the proton motive force and peptidoglycan are potential therapeutic targets by tiliquinol. Further, in various mouse infection models, favorable in vivo antibacterial efficacy with satisfied safety profiles of tiliquinol are confirmed. Conclusion: Tiliquinol is recognized as a novel therapeutic strategy against refractory MRSA-related infections, particularly those associated with osteomyelitis and implant-related complications.

  • Open Access

    Antibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 against acinetobacter baumannii

    by Pengfei She, Mengna Li, Yiqing Liu, Guanqing Huang, Shaowei Guo, Dan Xiao, Yelan Hong, Lihua Lu, Yong Wu

    Acinetobacter baumannii is an opportunistic pathogenic Gram-negative bacillus and one of the main pathogens causing hospital-acquired infections. It can cause varied types of infection, including m...


  • Open Access

    Repurposed bunamidine disrupts envelope energetics and induces ROS-mediated non-lytic killing

    by Guanqing Huang, Shaowei Guo, Dan Xiao, Yiqing Liu, Mengna Li, Lihua Lu, Yelan Hong, Yimin Li, Mingxiang Zou, Yong Wu

    Methicillin-resistant Staphylococcus aureus (MRSA) remains a major public health threat due to its multidrug resistance, biofilm formation, and persistence, which collectively limit the effectiveness of current antibiotics. Here we characterize bunamidine hydrochloride (BUN), a repurposed benzimidazole derivative, as a potent anti-MRSA candidate. Across clinical and reference isolates, BUN displayed low MIC/MBC values (4–8 μg/mL), rapid bactericidal activity, and consistent efficacy in both planktonic and biofilm-associated populations. BUN eradicated persister cells within hours, while exhibiting a markedly reduced propensity for resistance development compared with ciprofloxacin. Mechanistic analyses revealed that BUN disrupts envelope energetics—causing membrane depolarization, collapse of the proton motive force, ATP depletion, and lipid disorder—without pore formation. These events triggered amplification of reactive oxygen species (ROS), which acted as critical execution factors for bacterial killing. Hemolysis assays confirmed selective compatibility with mammalian membranes, consistent with a non-lytic mode of action. In murine abscess and wound infection models, which represent early acute infection stages rather than established biofilm or chronic conditions, topical BUN treatment reduced bacterial burden, accelerated wound closure, and alleviated inflammation without apparent toxicity. These results demonstrate early therapeutic efficacy, tissue-protective, and anti-inflammatory effects in acute infection settings. While the current in vivo models support antibacterial efficacy during early infection, evaluation in established biofilm or chronic infection models will be an important direction for future studies.


  • Open Access

    Repurposing bunamidine hydrochloride as a potent antimicrobial agent targeting vancomycin-resistant Enterococcus membranes

    by Pengfei She, Guanqing Huang, Shaowei Guo, Dan Xiao, Yiqing Liu, Mengna Li, Lihua Lu, Yelan Hong, Yimin Li, Linying Zhou, et al.

    Vancomycin-resistant enterococci (VRE) are a major cause of hospital-acquired infections, with limited treatment options due to rising antibiotic resistance. Targeting bacterial membranes offers a promising alternative to conventional therapies. In this study, we investigated the antimicrobial activity and mechanism of action of bunamidine hydrochloride (BUN) against VRE. BUN exhibited potent bactericidal effects against both VRE and vancomycin-susceptible enterococci (VSE), with minimum inhibitory concentrations (MICs) ranging from 2 to 4 µg/mL. BUN significantly inhibited biofilm formation and eradicated biofilm-embedded persister cells. Mechanistic studies demonstrated that BUN disrupts bacterial membrane integrity, increasing permeability and depolarization, as confirmed by SYTOX Green staining, DiSC3(5) fluorescence analysis, and electron microscopy. Molecular dynamics simulations further revealed that BUN selectively interacts with phosphatidylglycerol, a key bacterial membrane phospholipid, leading to membrane destabilization. In vivo studies using murine infection models showed that BUN effectively reduced bacterial burden and promoted wound healing without notable toxicity. These findings highlight BUN as a promising antimicrobial agent with membrane-targeting activity against VRE. Its potent bactericidal action, low propensity for resistance development, and favorable in vivo efficacy suggest potential for therapeutic application in treating multidrug-resistant infections. IMPORTANCE: The global rise of vancomycin-resistant enterococci (VRE) poses serious challenges in clinical treatment due to limited therapeutic options and rapid resistance development. This study identifies bunamidine hydrochloride (BUN), a previously approved antiparasitic agent, as a potent membrane-targeting antimicrobial with rapid bactericidal activity against both planktonic and biofilm-associated VRE. By selectively interacting with bacterial phosphatidylglycerol, BUN disrupts membrane integrity and inhibits persister cells, while maintaining low cytotoxicity and high in vivo efficacy in murine infection models. Our findings highlight the potential of drug repurposing strategies to accelerate the discovery of effective antibiotics and provide a promising candidate for future clinical management of multidrug-resistant bacterial infections.


  • Open Access

    Drug Repurposing: An Emerging Strategy in Staphylococcus aureus Infections

    by Yimin Li, Pengfei She, Yiqing Liu, Shaowei Guo, Guanqing Huang, Dan Xiao, Yong Wu

    Yimin Li, Pengfei She, Yiqing Liu, Shaowei Guo, Guanqing Huang, Dan Xiao, and Yong Wu. J. Microbiol. Biotechnol. 2025;35:1-16. https://doi.org/10.4014/jmb.2507.07048


  • Open Access

    Metagenomic next-generation sequencing for pathogen detection of pulmonary infections in persons living with HIV

    by Yapeng Zhang, Shaowei Guo, Lihua Lu, Yimin Li, Yong Wu

    This study aimed to evaluate the diagnostic utility of metagenomic next-generation sequencing (mNGS) in detecting pulmonary infections in persons living with HIV(PLWH). We conducted a retrospective study involving 246 PLWH with pulmonary infections. Bronchoalveolar lavage fluid (BALF) specimens were collected from all patients. mNGS and traditional microbial cultures were performed in parallel to compare the differences in pathogen identification. Patients were stratified by immune status based on CD4+ T cell counts, and the association between pathogen profiles and immunodeficiency severity was analyzed. mNGS demonstrated a significantly higher pathogen detection sensitivity (98.0%) compared to traditional cultures (32.1%). The spectrum of pathogens detected by mNGS and culture methods differed significantly. mNGS identified 123 pathogenic microorganisms, whereas cultures detected only 17. mNGS detected additional pathogens, including viruses (e.g., Epstein-Barr virus and cytomegalovirus) and fastidious microorganisms (e.g., Pneumocystis jirovecii). Furthermore, mNGS revealed a significant correlation between PLWH-associated immunodeficiency and pathogen profiles. The diversity of pathogens, particularly fungi and viruses, increased with declining CD4+ T cell counts (p < 0.05). mNGS comprehensively characterizes the complex pathogen spectrum in PLWH-associated pulmonary infections, significantly enhancing detection sensitivity for mixed and fastidious infections, thereby guiding targeted anti-infective therapy. Immunosuppression severity strongly correlates with opportunistic pathogen profiles and the risk of specific pathogen detection, highlighting the importance of immune status-guided clinical strategies. mNGS serves as a valuable adjunct to conventional diagnostic methods, enhancing the detection and prognostic assessment of infectious complications in PLWH.